Related Experiment Video
Updated: Mar 10, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
ANALYSIS OF SHORT-CHAIN FATTY ACIDS AND ASSOCIATION WITH GLUCAGON-LIKE PEPTIDE-1 IN HEALTHY, OBESE, PREDIABETES AND
1Yildiz Technical University, Faculty of Arts and Sciences - Chemistry.
Context:
Short-chain fatty acids (SCFAs) play a critical role in host metabolism, both directly and through specific G protein-coupled receptors, and may provide a link between glucose and lipid metabolism. This study aimed to compare fecal SCFA concentrations and to evaluate associations between SCFAs and glucagon-like peptide 1 (GLP-1) in individuals with type 2 diabetes (T2DM), prediabetes, obesity, and health.
Subjects And Methods:
The study included 60 volunteers in four groups: T2DM (n= 15), prediabetes (n= 15), obesity (n= 15), and healthy individuals (n= 15). We analyzed fecal SCFA and GLP-1 concentrations by HPLC-UV and ELISA method, respectively.
Results:
In comparison to healthy individuals, obese, prediabetic and T2DM exhibited notably elevated total SCFA levels respectively (p=0.019, p=0.017, p=0.024). Acetic acid concentration showed an increase in both obese and prediabetic groups compared to the healthy group (p=0.02, p=0.017). Butyric acid concentration was elevated in T2DM and prediabetic groups in comparison to both healthy and obese groups (p=0.024, p=0.017, p=0.07, p=0.56). The GLP-1 levels significantly decreased in the obese and prediabetic groups compared to the healthy and T2DM groups (p=0.00, p=0.021, p=0.000, p=0.005). GLP-1 was correlated with acetic acid, butyric acid, and the total SCFA concentrations in the T2DM and obese groups (r= 0.479, p= 0.098; r= 0.441, p= 0.099; r= 0.654, p= 0.015, respectively) while there was no correlation in the prediabetic group.
Conclusion:
Our results extend the knowledge on the alteration of SCFA levels in the states of obesity, prediabetes, and T2DM and enrich the understanding of the relationship between SCFAs and GLP-1.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Diabetes: Symptoms, Diagnosis, and Complications
Hypoglycemia and Glucagon
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
![Assessment of Gastric Emptying in Non-obese Diabetic Mice Using a [13C]-octanoic Acid Breath Test](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F50301.jpg&w=3840&q=50)
